2019 Press Releases

Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015
DateTitle 
03/18/19NantHealth® and Northwest Fire Fighters Benefits Trust (NWFFT) Join Forces to Provide GPS Cancer® and Liquid GPS to Trust Covered Members
CULVER CITY, Calif.--(BUSINESS WIRE)--Mar. 18, 2019-- NantHealth, Inc. (NASDAQ: NH), announced an agreement with Northwest Fire Fighters Benefits Trust (NWFFT), one of the largest firefighter healthcare trusts in the U.S., to ensure all NWFFT covered plan members with access to NantHealth’s GPS Cancer and Liquid GPS molecular profiling tests. Comprehensive molecular information may enable physicians to make personalized treatment strategies for cancer ba... 
Printer Friendly Version
02/14/19NantHealth® and NantOmics to Reveal New Research Demonstrating Importance of Examining RNA Expression and Individual Biomarkers in Cancer Testing
Findings to be presented at the 2019 American Society of Clinical Oncology’s Genitourinary Cancers Symposium SAN FRANCISCO & CULVER CITY, Calif.--(BUSINESS WIRE)--Feb. 14, 2019-- Scientific teams from NantHealth (NASDAQ: NH) and NantOmics will present two posters at the American Society of Clinical Oncology’s (ASCO) Genitourinary Cancers Symposium this week. The two companies, respective leaders in molecular profiling research and g... 
Printer Friendly Version
02/12/19NantHealth® Debuts Multiple Connected Care Initiatives at HIMSS
Collaboration with Leading Kidney Care Vendors, Intelligent Health and Connected Care Showcased CULVER CITY, Calif. & ORLANDO, Fla.--(BUSINESS WIRE)--Feb. 12, 2019-- NantHealth, Inc. (NASDAQ: NH), a leader in connected care solutions, will unveil a series of new initiatives designed to improve patient outcomes and provider satisfaction at the 2019 Healthcare Information and Management Systems Society (HIMSS) Annual Conference and Exhibition ... 
Printer Friendly Version
01/04/19NantCell Announces New Celgene Investment
Immunotherapy Company Will Present Findings at the JP Morgan Healthcare Conference in San Francisco on January 7thSecond Round Crossover Funding Brings Celgene's Investment to $105M in NantCell Valued at $4 BillionCurrently Enrolling Patients in Advanced Stage Trials in 15 Indications for Registration IntentDeep Pipeline Of 28 Unique Molecules With 14 First in Human Studies in Over 1,000 Patients to DateLos Angeles, CA, January 4, 2019 – NantCell and its founder Dr. Patrick Soon-Shiong announced... 
Printer Friendly Version